ReviewFrontiers in nephrology2026
Research advances on acute kidney injury and brain dysfunction.
Review in Frontiers in nephrology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Acute kidney injury (AKI) is a prevalent critical clinical condition primarily characterized by a sharp deterioration of renal function within 48 hours. Accumulating clinical evidence has demonstrated that AKI predisposes patients to multisystem complications, among which renal-brain axis dysfunction is well recognized. This condition manifests as delirium, coma and stroke, also elevates the risk of chronic cognitive impairment, dementia and depression. Such complications not only increase short-term all-cause mortality but also severely impair the long-term quality of life in survivors, thereby placing a substantial socioeconomic burden on global healthcare systems. Current mechanistic investigations into AKI-associated brain dysfunction have predominantly centered on canonical pathological pathways, including systemic inflammatory response, oxidative stress, hippocampal neuronal injury, uremic toxin accumulation and others. Emerging evidence indicates that insulin resistance (IR) is highly prevalent in AKI patients and closely correlated with the pathophysiological progression of AKI. We will discuss the specific role of IR in AKI-induced cognitive impairment. Additionally, this review highlights the prospective application of combined multimodal neuroimaging and machine learning algorithms. By integrating readily available multidimensional clinical data, the establishment of early risk prediction models for AKI-related brain dysfunction can facilitate timely identification and precise intervention for high-risk populations. Furthermore, we elaborate the therapeutic potential of targeted anti-inflammatory strategies and natural bioactive compounds in ameliorating AKI-associated brain dysfunction. Collectively, this review provides novel insights for the development of optimized, safe and effective clinical interventions in the future.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.